SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
GZMO
An SI Board Since November 1998
Posts SubjectMarks Bans Symbol
438 23 0 GZMO
Emcee:  mike mulhearn Type:  Unmoderated
Introduction Market Data Compact
Monday November 16, 8:38 am Eastern Time

Company Press Release

SOURCE: Genzyme Molecular Oncology

Genzyme Molecular Oncology Stock Begins Trading Today

Shares Distributed to Genzyme General Shareholders

CAMBRIDGE, Mass., Nov. 16 /PRNewswire/ -- Genzyme Corp. announced that Genzyme Molecular Oncology common stock begins trading today on the Nasdaq National Market under the ticker symbol GZMO. There are approximately 12.7 million shares outstanding.

In addition, Genzyme Molecular Oncology shares will be distributed today as a tax-free dividend to Genzyme General (Nasdaq: GENZ - news) shareholders of record as of November 2, 1998. The dividend is 0.10805 share of Genzyme Molecular Oncology common stock for each share of Genzyme General owned. Cash will be paid for fractional shares at $7.00 per share.

Genzyme Molecular Oncology is developing a new generation of cancer products, focusing on cancer vaccines and inhibitors of angiogenesis. The company has completed two phase I cancer vaccine trials in melanoma and plans to begin three additional clinical trials in melanoma, breast cancer, and ovarian cancer in the next year.

Genzyme Molecular Oncology has formed over two dozen commercial and academic collaborations since its inception in June 1997. Most recently, the company announced that it had licensed its p53 gene therapy patent rights to Schering-Plough Corporation [NYSE:SGP - news]. Under the terms of this agreement, Genzyme Molecular Oncology received a $5 million up-front payment and could receive in excess of $35 million in patent, product development and sales milestone fees, in addition to royalties on product sales. In addition to the p53 patent license, the two companies have a separate existing research and option agreement that could contribute significant revenue to Genzyme Molecular Oncology.

Genzyme Molecular Oncology has also entered into collaborations with Merck & Co., Warner-Lambert, and Bayer Corporation. The company's academic collaborators include the National Cancer Institute, the Dana Farber Cancer Institute, and the Ludwig Cancer Research Institute.

Genzyme Molecular Oncology had cash and short term investments of $8.1 million as of September 30, 1998, and has access to a $30 million equity line of credit from Genzyme General. Genzyme Molecular Oncology anticipates that these funds, in addition to revenues, will be sufficient to cover its operating costs for the next three years.

Genzyme Molecular Oncology is developing novel cancer therapeutics and diagnostics using four gene-based technologies: gene discovery, gene therapy, small-molecule drug discovery, and genetic diagnostics. A division of Genzyme Corp., Genzyme Molecular Oncology has its own common stock intended to reflect its economic value and track its performance.

This press release contains forward-looking statements concerning the commencement of clinical trials, the ability of Genzyme Molecular Oncology and Schering-Plough to develop and commercialize products under its agreements and of Genzyme Molecular Oncology to achieve performance milestones under those agreements, and the division's future operating results and cash requirements. Actual results may differ materially depending on, among other things, Genzyme Molecular Oncology and Schering-Plough's ability to successfully complete preclinical and clinical development of its products on a timely basis and to successfully market any products that are developed, the content and timing of decisions made by the U.S. Food and Drug Administration regarding Genzyme Molecular Oncology's products, Genzyme's ability to obtain and maintain patent and other proprietary rights protection of its products and services, acceptance of such products and services by the market and by third-party payers, the competitive environment for cancer therapeutics and diagnostics, and other risks described under the heading ''Factors Affecting Future Operating Results'' beginning on page 17 of the 1997 Genzyme Molecular Oncology Annual Report.

Genzyme's releases are on the World Wide Web at genzyme.com. They are also available from Genzyme's fax-on-demand service at 1-800-436-1443 within the United States or 1-201-521-1080 outside the United States.

SOURCE: Genzyme Molecular Oncology
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
438Genzyme annual report indicates that phase I/II Kidney cancer vacine results wilExtra Pale-5/3/2004
437>>FRAMINGHAM, Mass., Jan. 9 /PRNewswire-FirstCall/ -- Genzyme Molecular Ontuck-1/9/2003
436>>FRAMINGHAM, Mass., Dec. 10 /PRNewswire-FirstCall/ -- A team of Harvard Mtuck-12/10/2002
435>>FRAMINGHAM, Mass., Oct. 29 /PRNewswire-FirstCall/ -- In a scientific joutuck-10/29/2002
434FRAMINGHAM, Mass., Oct. 16 /PRNewswire-FirstCall/ -- Genzyme Corp. today reportenigel bates-10/16/2002
433Thanks for the dddmag pointer, Tuck. Parking the two Silico Insights PRs for funigel bates-10/14/2002
432Besides plain old borning cash, now would be an excellent time for Genzyme to buMike McFarland-10/12/2002
431One has to wonder if a little love ($) from Papa Genzyme might do wonders for thtuck-10/11/2002
430GZMO price is deteriorating again it seems, I nibbled on some over the past couMike McFarland-9/12/2002
429GZMO is about the only biotech I managed to sell at the right time (well into donigel bates-8/27/2002
428Another shameless hype laden PR--dripping with scientific goo, or is there sometMike McFarland-8/27/2002
427FRAMINGHAM, Mass., Aug. 27 /PRNewswire-FirstCall/ -- A new, rapid method of idennigel bates-8/27/2002
426I like GZMO's tech. Have been buying all the way down and getting crushed. SOROS-5/23/2002
425GZMO continues to crater on lowish volume; now ~1.5x cash. >>FRAMINGHAM, tuck-5/20/2002
424New Genomics Method Likely to Accelerate Completion of the Human Genome FRAMINGnigel bates-5/6/2002
423EP, This abstract appears to be the one referenced, but was published in Novembtuck-4/3/2002
422Tuesday April 2, 4:21 pm Eastern Time Press Release SOURCE: Genzyme Molecular OnExtra Pale-4/2/2002
421GZMO within a hair's breadth of lows, since the release of this earnings reptuck-3/21/2002
420>>FRAMINGHAM, Mass., Jan. 15 /PRNewswire-FirstCall/-- Genzyme Molecular Ontuck-1/15/2002
419Monday January 14, 9:16 am Eastern Time Press Release SOURCE: Genzyme Molecular Extra Pale-1/14/2002
418<< ExtraPale, my background is finance - note this post of mine from YahooSpekulatius-1/6/2002
417ExtraPale, my background is finance - note this post of mine from Yahoo which pujeffbas-1/6/2002
416The $32million boosted my declining view of gzmo/genz - with no way of knowing, Extra Pale-1/6/2002
415I do not trust GENZ either. They have huge conflicts of interest in managing thejeffbas-1/5/2002
414p53 article (thanks, Savant) msnbc.comExtra Pale-1/3/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News